"Halperin comes from The University of Texas MD Anderson Cancer Center, where he was an instrumental clinical and research leader in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine. He was the clinical medical director for MD Anderson's Gastrointestinal Center as it transformed into a multicampus service line, and director of clinical research operations in the Department of Gastrointestinal Medical Oncology during a period of dramatic reduction of trial activation timelines. He also served as chair of the NET Multidisciplinary Conference (Tumor Board) at MD Anderson and represented the institution on the Neuroendocrine and Adrenal Tumor guideline committee of the National Comprehensive Cancer Network (NCCN). He currently serves on the Board of Scientific Advisors of the NET Research Foundation, the Scientific Advisory Committee of the Healing NET Foundation and the Board of Directors and Symposium Committee of the North American Neuroendocrine Tumor Society." https://winshipcancer.emory.edu/newsroom/articles/2024/halperin-named-new-vice-chair-of-clinical-affairs-for-hematology-and-medical-oncology.php
"As a clinical investigator, Halperin is dedicated to providing world-class clinical care and developing novel therapies for patients with neuroendocrine tumors (NETs), which are tumors that develop from a diffuse network of neuroendocrine cells that make and release hormones into the bloodstream to control essential bodily functions. He has played a leading role in clinical trials of immunotherapy and radioligands for patients with NETs. He also collaborates with laboratory and population scientists to deepen our understanding of the molecular basis and clinical presentation of neuroendocrine tumors." https://winshipcancer.emory.edu/profiles/halperin-daniel.php
CHM Price at posting:
0.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)